Physician profile
Jeffrey Levine
NPI 1245225333
$2,463.04
in general payments reported to CMS, 2019-2025
20 companies · $71.20 in 2025
The $71.20 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $67.18 · 2021: $339 · 2022: $586 · 2023: $522 · 2024: $438 · 2025: $71.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $947.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $645.96 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $246.01 | 2019-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $84.08 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $78.93 | 2019-2024 | Ocaliva |
| Celgene Corporation | $67.14 | 2022-2023 | Zeposia |
| Pfizer INC. | $61.60 | 2019-2022 | |
| Janssen Biotech, INC. | $52.73 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $42.37 | 2022 | |
| Genzyme Corporation | $38.47 | 2022-2023 | |
| Ucb, INC. | $38.18 | 2019 | |
| Gilead Sciences, INC. | $27.44 | 2024 | |
| Daiichi Sankyo INC. | $19.29 | 2024 | Injectafer |
| Boston Scientific Corporation | $18.23 | 2022 | |
| Celltrion USA INC. | $18.18 | 2024 | Vegzelma |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.33 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.48 | 2024 | Rebyota |
| Ardelyx, INC. | $14.78 | 2022 | |
| Lilly USA, LLC | $14.53 | 2024 | Omvoh |
| Evoke Pharma, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.